Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE | Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Logo.jpg
Longeveron Announces Board of Directors Planned Transitions
10 mai 2024 16h05 HE | Longeveron
Longeveron announces planned transitions on its Board of Directors.
Longeveron Logo.jpg
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
02 mai 2024 08h03 HE | Longeveron
Longeveron to report Q1 2024 financial results on May 14, 2024.
Longeveron Logo.jpg
Longeveron to Present at the Planet MicroCap Showcase
25 avr. 2024 16h05 HE | Longeveron
Longeveron to present at investor conference - Planet MicroCap Showcase - May 1, 2024.
Longeveron Logo.jpg
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
18 avr. 2024 16h05 HE | Longeveron
Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
Longeveron Logo.jpg
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
17 avr. 2024 08h00 HE | Longeveron
Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.
Longeveron Logo.jpg
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
15 avr. 2024 08h30 HE | Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Longeveron Logo.jpg
Longeveron Announces Closing of $5.2 Million Public Offering
11 avr. 2024 17h17 HE | Longeveron
Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.
Longeveron Logo.jpg
Longeveron Announces Pricing of $5.25 Million Public Offering
08 avr. 2024 14h15 HE | Longeveron
Longeveron prices $5.15 million public offering with certain board member and insider participation.
Longeveron Logo.jpg
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
08 avr. 2024 08h30 HE | Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.